Needham Believes Neurocrine (NASDAQ: NBIX) Still Has Room to Grow

By Austin Angelo

Needham analyst Alan Carr reiterated a Buy rating on Neurocrine (NASDAQ: NBIX) on September 15 and set a price target of $58. The company’s shares closed on Friday at $56.71, close to its 52-week high of $60.

According to TipRanks.com, Carr is a 4-star analyst with an average return of 7.3% and a 44.3% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Neurocrine is Strong Buy and the average price target is $75.88, representing a 33.8% upside.

In a report issued on September 4, Jefferies also reiterated a Buy rating on the stock with a $66 price target.

The company has a one year high of $60 and a one year low of $37.35. Currently, Neurocrine has an average volume of 899.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neurocrine Biosciences, Inc. operates as a product based biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale on January, 1992 and is headquartered in San Diego, CA.